Blocking the peroxisome proliferator-activated receptor (PPAR): an overview

Area of Science:

• Biochemistry
• Pharmacology
• Molecular Biology

Background:

• Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors extensively studied for metabolic disorders.
• Significant advancements have been made in understanding PPAR physiology, pharmacology, and identifying novel activating compounds.
• Moderate PPAR activation may reduce side effects associated with traditional agonists.

Purpose of the Study:

• To provide an overview of molecular structures that block Peroxisome proliferator-activated receptor (PPAR) subtypes.
• To focus on the therapeutic applications of PPAR antagonists and partial agonists.
• To elucidate biological processes modulated by PPARs using specific modulators.

Main Methods:

• Literature review of existing studies on PPAR modulators.
• Analysis of molecular structures of PPAR antagonists and partial agonists.
• Evaluation of preclinical and clinical data on therapeutic applications.

Main Results:

• Identification of diverse chemical structures acting as PPAR antagonists and partial agonists.
• Evidence suggests partial agonists and antagonists offer a favorable therapeutic window with fewer side effects.
• These modulators are valuable tools for dissecting PPAR-mediated biological pathways.

Conclusions:

• PPAR antagonists and partial agonists represent promising therapeutic strategies for metabolic and other diseases.
• Targeting PPAR subtypes with specific modulators can lead to improved treatment outcomes.
• Further research into PPAR modulators will enhance understanding and application in medicine.